ABSTRACT
The severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) replication transcription complex (RTC) is a multi-domain protein responsible for replicating and transcribing the viral mRNA inside a human cell. Attacking RTC function with pharmaceutical compounds is a pathway to treating COVID-19. Conventional tools, e.g., cryo-electron microscopy and all-atom molecular dynamics (AAMD), do not provide sufficiently high resolution or timescale to capture important dynamics of this molecular machine. Consequently, we develop an innovative workflow that bridges the gap between these resolutions, using mesoscale fluctuating finite element analysis (FFEA) continuum simulations and a hierarchy of AI-methods that continually learn and infer features for maintaining consistency between AAMD and FFEA simulations. We leverage a multi-site distributed workflow manager to orchestrate AI, FFEA, and AAMD jobs, providing optimal resource utilization across HPC centers. Our study provides unprecedented access to study the SARS-CoV-2 RTC machinery, while providing general capability for AI-enabled multi-resolution simulations at scale. We acknowledge funding from NIH P41-GM10460, DOE CSGF (DE-FG02-97ER25308), Exascale Computing Project (17-SC-20-SC) and National Virtual Biotechnology Laboratory.Copyright © 2023 The American Society for Biochemistry and Molecular Biology, Inc.
ABSTRACT
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silico methodologies need to be improved both to select better lead compounds, so as to improve the efficiency of later stages in the drug discovery protocol, and to identify those lead compounds more quickly. No known methodological approach can deliver this combination of higher quality and speed. Here, we describe an Integrated Modeling PipEline for COVID Cure by Assessing Better LEads (IMPECCABLE) that employs multiple methodological innovations to overcome this fundamental limitation. We also describe the computational framework that we have developed to support these innovations at scale, and characterize the performance of this framework in terms of throughput, peak performance, and scientific results. We show that individual workflow components deliver 100 × to 1000 × improvement over traditional methods, and that the integration of methods, supported by scalable infrastructure, speeds up drug discovery by orders of magnitudes. IMPECCABLE has screened ∼1011 ligands and has been used to discover a promising drug candidate. These capabilities have been used by the US DOE National Virtual Biotechnology Laboratory and the EU Centre of Excellence in Computational Biomedicine. © 2021 ACM.
ABSTRACT
Emerging hardware tailored for artificial intelligence (AI) and machine learning (ML) methods provide novel means to couple them with traditional high performance computing (HPC) workflows involving molecular dynamics (MD) simulations. We propose Stream-AI-MD, a novel instance of applying deep learning methods to drive adaptive MD simulation campaigns in a streaming manner. We leverage the ability to run ensemble MD simulations on GPU clusters, while the data from atomistic MD simulations are streamed continuously to AI/ML approaches to guide the conformational search in a biophysically meaningful manner on a wafer-scale AI accelerator. We demonstrate the efficacy of Stream-AI-MD simulations for two scientific use-cases: (1) folding a small prototypical protein, namely ββα-fold (BBA) FSD-EY and (2) understanding protein-protein interaction (PPI) within the SARS-CoV-2 proteome between two proteins, nsp16 and nsp10. We show that Stream-AI-MD simulations can improve time-to-solution by ~50X for BBA protein folding. Further, we also discuss performance trade-offs involved in implementing AI-coupled HPC workflows on heterogeneous computing architectures. © 2021 ACM.
ABSTRACT
COVID-19 has claimed more than 2.7 × 106 lives and resulted in over 124 × 106 infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. We discuss innovations in computational infrastructure and methods that are accelerating and advancing drug design. Specifically, we describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational infrastructure to support these methods at scale. We discuss their implementation, characterize their performance, and highlight science advances that these capabilities have enabled. © 2021 ACM.